Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Multiple Myeloma 5Mucositis 2Febrile Neutropenia 2Unspecified Adult Solid Tumor, Protocol Specific 1Smoldering Multiple Myeloma 1Recurrence 1Rectal Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Hematologic Neoplasms 1Cytokine Release Syndrome 1Cryopyrin-Associated Periodic Syndromes 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 165Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 83Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT01802970 2021-10-08

Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

Baylor Research Institute

Phase 1 Completed
10 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡